Related Experiment Videos
Structure of a type II thymidine kinase with bound dTTP
Markus S Birringer1, Michael T Claus, Gerd Folkers
1Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Wolfgang-Pauli Strasse 10, 8093 Zurich, Switzerland.
FEBS Letters
|March 1, 2005
Summary
The structure of human cytosolic thymidine kinase (T2 enzyme) was determined, revealing differences from type I enzymes. This finding aids in developing new antiviral drugs and prodrugs.
Area of Science:
- Biochemistry
- Structural Biology
- Enzymology
Background:
- Human cytosolic thymidine kinase is crucial for DNA synthesis.
- Thymidine kinase enzymes are targets for antiviral therapies.
- Type I and Type II thymidine kinases exhibit structural and functional differences.
Purpose of the Study:
- To determine the structure of human cytosolic thymidine kinase (type II) in complex with its inhibitor.
- To compare the structure of type II thymidine kinase with known type I enzymes.
- To provide insights for developing novel antiviral agents.
Main Methods:
- X-ray crystallography was used to determine the enzyme-inhibitor complex structure.
- Biochemical assays were employed to analyze enzyme activity and specificity.
- Comparative structural analysis was performed against type I thymidine kinases.
Main Results:
- The first structure of a type II thymidine kinase, human cytosolic thymidine kinase, was elucidated.
- The type II enzyme possesses a unique zinc-binding domain with four cysteine residues.
- Unlike type I enzymes, type II thymidine kinase utilizes backbone hydrogen bonds for thymine binding, conferring distinct specificity.
Conclusions:
- The determined structure provides a foundation for understanding type II thymidine kinase function.
- Structural differences between type I and type II enzymes offer opportunities for selective drug design.
- This research facilitates the development of new antiviral drugs and prodrugs targeting thymidine kinase.